Zacks Market Edge Highlights: United Technologies, Norfolk Southern, Arista Networks, Fortescue Metals And Shin-Etsu Chemical
Zacks Investment Research | Apr 10, 2019 10:40PM ET
For Immediate Release
Chicago, IL – April 11, 2019 – Zacks Market Edge is a podcast hosted weekly by cks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here:
Get The News You Want
Get The News You Want
Get The News You Want
(Please use the Soundcloud link from this URL for the PR. Thanks: https://www.zacks.com/stock/news/377815/stocks-to-combat-recession-worries )
Get The News You Want
Stocks to Combat Recession Worries
Get The News You Want
Welcome to Episode #172 of the Zacks Market Edge Podcast.
Get The News You Want
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
Get The News You Want
In this episode, Tracey is joined by Zacks Chief Equity Strategist, John Blank, to talk about their favorite topic: is the US economy in a recession?
Get The News You Want
And if so, how do you invest for it?
Get The News You Want
Tracey and John first covered this subject all the way back in Episode #20 of the podcast, in February 2016, which was titled “Why There Won’t Be a Recession in 2016.”
Get The News You Want
And, actually, there wasn’t.
Get The News You Want
Signs of a Recession
Get The News You Want
But it’s worth looking, again, at what is one of the most important indicators of a recession: employment.
Get The News You Want
For the week ending March 30, the jobless claims fell 10,000 to 202,000, which was back to a 49-year low.
Get The News You Want
The March employment report also showed unemployment unchanged at 3.8%.
Get The News You Want
Additionally, Bank of America (NYSE:BAC) announced that it was raising its minimum wage to $17, with it rising to $20 an hour, by 2021.
Get The News You Want
That’s a sign that the job market remains tight. Companies don’t raise wages to be nice.
Get The News You Want
Conclusion?
Get The News You Want
The United States isn’t in a recession.
Get The News You Want
So why is everyone so nervous about one?
Get The News You Want
Stocks for a Recession
Get The News You Want
It doesn’t hurt for investors to be prepared as a recession is, ultimately, inevitable.
Get The News You Want
1. United Technologies (NYSE:UTX) is planning on splitting into three companies by 2020 with Otis and Carrier being separated during that time. In the meantime, the shares are underperforming the S&P 500 and a have a forward P/E of 16.9.
Get The News You Want
2. Norfolk Southern (NYSE:NSC) is busting out to 5-year highs but earnings are expected to be up 9.3% in 2019 and another 14.7% in 2020 for this railroad. The rails may be old school but investors have been cashing in.
Get The News You Want
3. Arista Networks (NYSE:ANET) which provides software driven cloud networking, has been a big momentum stock in 2019. Shares are up 51% year-to-date. It’s not cheap, with a forward P/E of 34, but you’re buying the growth story.
Get The News You Want
4. Fortescue Metals Group (OTC:FSUGY) is an Australian iron ore company. It’s trading at just 11.6x earnings even though shares have soared 96% year-to-date. As China’s growth ramps back up, the Australian commodity plays should benefit.
Get The News You Want
5. Shin-Etsu Chemical (OTC:SHECY) is the 9th largest chemical company in Japan. One of its specialties is chip chemicals. Shares are up 21% year-to-date.
Get The News You Want
What else should you know about investing for a possible recession?
Get The News You Want
Tune into this week’s podcast to find out.
Get The News You Want
Breakout Biotech Stocks with Triple-Digit Profit Potential
Get The News You Want
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Get The News You Want
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Get The News You Want
Get The News You Want
Follow us on Twitter: https://twitter.com/zacksresearch
Get The News You Want
Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Get The News You Want
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Get The News You Want
Media Contact
Get The News You Want
Zacks Investment Research
Get The News You Want
800-767-3771 ext. 9339
Get The News You Want
support@zacks.com
Get The News You Want
https://www.zacks.com/performance
Get The News You Want
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit Zacks Investment Research
Get The News You Want
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.